| Περιγραφή: |
Debdulal Chakraborty,1 Tushar Kanti Sinha,1 Sourav Sinha,2 Rupak Kanti Biswas,2 Aniruddha Maiti,3 Krishnendu Nandi,2 Dinesh Rungta,1 Ranabir Bhattacharya1 1Vitreo-Retina Services, Disha Eye Hospitals, Kolkata, WB, India; 2Vitreo-retina Services, Nethralayam Superspeciality Eye Care, Kolkata, WB, India; 3Vitreo-Retina Services Global Eye Hospital, Kolkata, WB, IndiaCorrespondence: Debdulal Chakraborty, Vitreo-retinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India, Tel +91 33 6636 0000, Email devdc@rediffmail.comPurpose: To compare the efficacy and safety of biosimilar ranibizumab (Razumab®) versus innovator ranibizumab (Lucentis®/Accentrix®) in the treatment of myopic choroidal neovascular membrane (mCNVM).Methods: This retrospective, multicenter study included treatment-naïve patients with mCNVM between January 2021 and December 2023. Patients received intravitreal injections of either innovator or biosimilar ranibizumab, following a pro re nata (PRN) protocol. Inclusion criteria were: age ≥ 18years, axial length > 26.5 mm or spherical equivalent ≥ – 6.00 D, diagnosis confirmed by multimodal imaging, and a minimum 12-month follow-up. Outcomes assessed included change in best-corrected visual acuity (BCVA; ETDRS letters), central macular thickness (CMT), intraocular pressure (IOP), injection frequency, and safety profile.Results: A total of 80 eyes were analyzed (Group A: Innovator, n=38; Group B: Biosimilar, n=42). Mean BCVA improved from 51.0 ± 16.5 to 64.5 ± 5.5 ETDRS letters in the Innovator group and from 52.5 ± 16.5 to 64.5 ± 4.5 in the Biosimilar group at 12 months (p > 0.05). CMT reduced significantly in both groups (Innovator: from 332.03 ± 39.22 μm to 268.32 ± 18.78 μm; Biosimilar: from 315.03 ± 44.20 μm to 271.12 ± 20.39 μm; (p > 0.05). The mean number of injections was 2.68 ± 0.51 in the Innovator Ranibizumab group and 2.71 ± 0.49 in the Biosimilar Ranibizumab group. IOP remained stable in both cohorts, and no significant ocular or systemic adverse events were observed.Conclusion: Biosimilar ranibizumab demonstrated non-inferior visual and anatomical outcomes compared to innovator ranibizumab in the treatment of mCNVM, with a similar safety profile and treatment burden.Keywords: myopia, myopic CNVM, anti VEGF, ranibizumab, biosimilar ranibizumab |